1月20日,康诺亚和诺诚健华联合宣布,两家公司及其双方的合资公司共同和Prolium Bioscience(下称Prolium)达成许可合作,授权Prolium开发和商业化CD20×CD3双特异性抗体ICP-B02(CM355)。虽然这起交易的首付款项不高,但对于康诺亚而言,其已通过从去年开始的四笔NewCo(合作授权模式)“出海”交易找到一条快速回流资金之道;而对于诺诚健华而言,这是其自奥布替尼...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.